Dicerna Pharmaceuticals Inc - FORM 10-K - EX-23.1 - EXHIBIT 23.1 - February 28, 2020

Attached files

file filename
EX-10.32 - EXHIBIT 10.32 - Dicerna Pharmaceuticals Incexhibit1032.htm
EX-32.1 - EXHIBIT 32.1 - Dicerna Pharmaceuticals Incexhibit321.htm
EX-31.2 - EXHIBIT 31.2 - Dicerna Pharmaceuticals Incexhibit312.htm
EX-31.1 - EXHIBIT 31.1 - Dicerna Pharmaceuticals Incexhibit311.htm
EX-21.1 - EXHIBIT 21.1 - Dicerna Pharmaceuticals Incexhibit211.htm
EX-10.56 - EXHIBIT 10.56 - Dicerna Pharmaceuticals Incexhibit1056.htm
EX-10.55 - EXHIBIT 10.55 - Dicerna Pharmaceuticals Incexhibit1055.htm
EX-10.54 - EXHIBIT 10.54 - Dicerna Pharmaceuticals Incexhibit1054.htm
EX-10.53 - EXHIBIT 10.53 - Dicerna Pharmaceuticals Incexhibit1053.htm
EX-10.52 - EXHIBIT 10.52 - Dicerna Pharmaceuticals Incexhibit1052.htm
EX-10.48 - EXHIBIT 10.48 - Dicerna Pharmaceuticals Incexhibit1048.htm
EX-10.47 - EXHIBIT 10.47 - Dicerna Pharmaceuticals Incexhibit1047.htm
EX-10.46 - EXHIBIT 10.46 - Dicerna Pharmaceuticals Incexhibit1046.htm
EX-10.33 - EXHIBIT 10.33 - Dicerna Pharmaceuticals Incexhibit1033.htm
EX-10.31 - EXHIBIT 10.31 - Dicerna Pharmaceuticals Incexhibit1031.htm
EX-10.30 - EXHIBIT 10.30 - Dicerna Pharmaceuticals Incexhibit1030.htm
EX-10.29 - EXHIBIT 10.29 - Dicerna Pharmaceuticals Incexhibit1029.htm
EX-4.1 - EXHIBIT 4.1 - Dicerna Pharmaceuticals Incexhibit41.htm
10-K - 10-K - Dicerna Pharmaceuticals Inca2019_drnax10k.htm


Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements No. 333-234572 on Form S-3ASR, Nos. 333-202687, 333-214082, 333-223778, and 333-224989 on Form S-3 and in Registration Statement Nos. 333-193795, 333-210071, 333-223648, and 333-233149 on Form S-8 of our reports dated February 27, 2020, relating to the consolidated financial statements of Dicerna Pharmaceuticals, Inc. and the effectiveness of Dicerna Pharmaceuticals, Inc.'s internal control over financial reporting, appearing in this Annual Report on Form 10-K of Dicerna Pharmaceuticals, Inc. for the year ended December 31, 2019.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 27, 2020



Dicerna Pharmaceuticals Inc Reports